Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
2(29%)
Results Posted
100%(2 trials)
Terminated
2(29%)

Phase Distribution

Ph phase_3
2
29%
Ph phase_4
1
14%
Ph phase_2
4
57%

Phase Distribution

0

Early Stage

4

Mid Stage

3

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
4(57.1%)
Phase 3Large-scale testing
2(28.6%)
Phase 4Post-market surveillance
1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

2

trials recruiting

Total Trials

7

all time

Status Distribution
Active(2)
Completed(2)
Terminated(3)

Detailed Status

Completed2
Terminated2
Withdrawn1
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
2
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 24 (57.1%)
Phase 32 (28.6%)
Phase 41 (14.3%)

Trials by Status

completed229%
withdrawn114%
active_not_recruiting114%
terminated229%
recruiting114%

Recent Activity

2 active trials
Showing 5 of 7
recruitingphase_2

Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

NCT07027124
active_not_recruitingphase_2

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

NCT01746849
completedphase_2

A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment

NCT03572387
withdrawnphase_2

Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer

NCT04331717
completedphase_3

Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

NCT00002597
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07027124Phase 2

Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

Recruiting
NCT01746849Phase 2

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

Active Not Recruiting
NCT03572387Phase 2

A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment

Completed
NCT04331717Phase 2

Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer

Withdrawn
NCT00002597Phase 3

Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

Completed
NCT02749825Phase 4

Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer

Terminated
NCT00243646Phase 3

Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial

Terminated

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7